» Articles » PMID: 17846508

Marked Expansion of CD11c+CD8+ T-cells in Melanoma-bearing Mice Induced by Anti-4-1BB Monoclonal Antibody

Overview
Journal Mol Cells
Publisher Elsevier
Date 2007 Sep 12
PMID 17846508
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

4-1BB (CD137), a member of the tumor necrosis factor receptor superfamily, is expressed on activated T-cells, and 4-1BB signaling due to interaction with 4-1BB ligand or ligation with anti-4-1BB monoclonal antibody (mAb) costimulates T cells. It has been shown that administration of anti-4-1BB mAb induces anti-tumor immunity in mice, but the nature of the cellular subsets responsible for this immunity is uncertain. In this study we found that anti-4-1BB mAb administration to B16F10 melanoma-bearing mice induced marked expansion of CD11c+CD8+ T-cells in parallel with suppression of pulmonary tumors. The mAb-treated mice produced higher levels of IFN- in their tumor tissues, spleen and lymph nodes than mice exposed to control antibody. When the CD11c+CD8+ T-cells were purified and re-stimulated in vitro, they produced high levels of the Th1 cytokines, IFN- and IL-2, but low levels of the Th2 cytokines, IL-4 and IL-10. Furthermore, they expressed high levels of 4-1BB and CD107a, a marker of activated cytotoxic T-lymphocytes. Our results suggest that CD11c+CD8+ T-cells play a role in the anti-tumor immunity induced by anti-4-1BB mAb.

Citing Articles

Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity.

Hamouda A, Filtjens J, Brabants E, Kancheva D, Debraekeleer A, Brughmans J Nat Commun. 2024; 15(1):10635.

PMID: 39639025 PMC: 11621563. DOI: 10.1038/s41467-024-54877-9.


Brief Communication: Combination of an MIP3α-Antigen Fusion Therapeutic DNA Vaccine With Treatments of IFNα and 5-Aza-2'Deoxycytidine Enhances Activated Effector CD8+ T Cells Expressing CD11c in the B16F10 Melanoma Model.

Fessler K, Zhang J, Sandhu A, Hui Y, Kapoor A, Ayeh S J Immunother. 2024; 48(1):1-5.

PMID: 39397434 PMC: 11617275. DOI: 10.1097/CJI.0000000000000542.


Combination of a MIP3α-antigen fusion therapeutic DNA vaccine with treatments of IFNα and 5-Aza-2'Deoxycytidine enhances activated effector CD8+ T cells expressing CD11c in the B16F10 melanoma model.

Fessler K, Zhang J, Sandhu A, Hui Y, Kapoor A, Ayeh S Res Sq. 2023; .

PMID: 37645859 PMC: 10462250. DOI: 10.21203/rs.3.rs-3243336/v2.


Anti-4-1BB antibody-based combination therapy augments antitumor immunity by enhancing CD11cCD8 T cells in renal cell carcinoma.

Ju S, Park S, Joe Y, Chung H, An W, Kim B Oncol Lett. 2022; 23(2):43.

PMID: 34976155 PMC: 8674882. DOI: 10.3892/ol.2021.13161.


B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8 tumor-infiltrating lymphocytes.

You G, Lee Y, Kang Y, Park H, Park K, Kim H Sci Adv. 2021; 7(3).

PMID: 33523913 PMC: 7810375. DOI: 10.1126/sciadv.aax3160.